U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.86 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.14 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +0.03 (+0.03%)
     
  • Gold

    1,812.90
    +11.40 (+0.63%)
     
  • Silver

    19.85
    +0.19 (+0.96%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.54%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • GBP/USD

    1.2100
    -0.0075 (-0.62%)
     
  • USD/JPY

    135.2540
    -0.4740 (-0.35%)
     
  • BTC-USD

    19,306.45
    -2.56 (-0.01%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.38 (-1.73%)
     

InMed Pharmaceuticals Closes $5M Direct, Private Placement Offerings

·3 min read

Los Angeles, CA - (NewMediaWire) - June 07, 2022 - - (InvestorBrandNetwork via NewMediaWire) - IBN, a multifaceted financial news, content creation and publishing company, is utilized by both public and private companies to optimize investor awareness and recognition.

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has closed on its registered direct offering and concurrent private placement with a single healthcare-focused institutional investor; the offerings were priced at-the-market under Nasdaq rules. According to the announcement, for the registered direct offering, INM issued 4,079,256 common shares at a purchase price of $0.858 per share (or prefunded warrant in lieu thereof). For the concurrent private placement, InMed issued and sold to the investor 1,748,250 common shares (or prefunded warrant in lieu thereto); those shares were offered at the same purchase price as those associated with the registered direct offering. InMed noted that it also issued unregistered preferred investment options to the investor; those investment options allowed for the purchase of up to 5,827,506 common shares. The announcement also outlined amendments to existing warrants that had been previously issued to the same investor. According to the announcement, the company could see gross proceeds from both offerings reach an estimated $5 million. InMed anticipates using the net proceeds from the offerings to continue pipeline development and advance commercial activities as well for general working capital purposes.

To view the full press release, visit https://cnw.fm/91OXR

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and is dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company's newsroom at https://cnw.fm/INM

About IBN

IBN has introduced 50+ distinct investor-focused brands over the last 15+ years and has leveraged these unique brands to amass a collective audience of millions of social media followers. In conjunction with 5,000+ syndication partnerships, IBN's broad-based investor-facing brands help fulfill the diverse demands and needs of our rapidly growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, harnessing the energy and experience of our team of specialized experts to exceed the expectations of each of our client-partners.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com

View the original release on www.newmediawire.com